OTC:UEEC
United Health Products, Inc.
A distressed OTC entity with zero reported revenue, massive accumulated deficits, and negative operating cash flow despite negligible operating costs.
Key Metrics
Investment Thesis
Bull Case
A speculative investor might buy UEEC as a deep value play where the market has already priced in the worst-case scenario given the zero revenue and massive deficit. The absence of cost of goods sold and operating expenses suggests potential for a business model pivot or hidden asset realization not yet reflected on the books. The OTC listing provides a low-cost entry point for investors seeking high-volatility turnaround opportunities with minimal downside relative to current market cap.
Bear Case
The stock is fundamentally worthless given zero revenue, negative cash flow from operations, and a shareholders' equity deficit of $2.4M. Without any income generation or cost structure to support future profitability, the company faces inevitable delisting or liquidation risks. The massive retained earnings deficit indicates that the business has burned through its capital base without achieving commercial viability.
About United Health Products, Inc.
United Health Products, Inc. (UEEC) is a publicly traded entity listed on the OTC market with no reported revenue or cost of goods sold in the latest fiscal period. The company has recorded significant net losses over the past three years and holds a substantial deficit in retained earnings relative to its minimal cash reserves. Despite having zero current operating expenses, the firm reports non-cash adjustments that significantly exceed its nominal net income losses.
Analysis
Management Discussion
Management has failed to generate any top-line revenue in the latest reporting period, resulting in a net loss of $2.0M that flows directly into an enlarged deficit. Operating cash flow turned negative at -$1.2M while non-cash adjustments totaling nearly $654k obscure the true economic burn rate of the business. The balance sheet reflects a capitalization structure dominated by paid-in capital rather than organic growth or profitable operations.
Industry Overview
The broader healthcare products industry typically generates substantial revenue and maintains positive gross margins, which contrasts sharply with UEEC's current zero-revenue status. Most competitors in this sector hold positive working capital and invest heavily in research and development to drive product innovation. The lack of inventory and cost data suggests UEEC has exited the traditional manufacturing or distribution model entirely.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $37.5K | $0 | $0 |
| Cost of Revenue | $18.6K | $0 | $0 |
| Gross Profit | $18.9K | $0 | $0 |
| Operating Expenses | $2.8M | $2.4M | $2.0M |
| Operating Income | $-2.8M | $-2.4M | $-2.0M |
| R&D | $624.6K | $598.8K | $355.9K |
| G&A | $2.2M | $1.8M | $1.7M |
| Stock-Based Comp | $483.4K | — | — |
| D&A | — | $4.0K | $4.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $17.0K | $40.5K | — |
| Pre-Tax Income | $-2.8M | $-2.4M | $-2.0M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-2.8M | $-2.4M | $-2.0M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $1.7M | $-2.6M | $-2.0M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $1.7M | $-2.6M | $-2.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $71.0K | $151.8K | $191.7K |
| Cash & Equivalents | $13.4K | — | — |
| Inventory | $34.7K | $33.6K | $0 |
| Prepaid Expenses | $22.9K | $22.8K | $22.8K |
| Other Current Assets | $0 | $95.4K | $168.9K |
| Long-Term Assets | $279.5K | $132.8K | $78.3K |
| Operating Leases | — | $76.5K | $47.1K |
| Other LT Assets | — | $56.3K | $31.2K |
| Total Assets | $350.5K | $284.6K | $270.0K |
| Current Liabilities | $2.4M | $2.0M | $1.6M |
| Current Leases | — | $28.8K | $33.3K |
| Other Current Liab | — | $1.7M | $1.6M |
| Long-Term Liabilities | $0 | $48.5K | $1.1M |
| LT Operating Leases | — | $48.5K | $15.2K |
| Other LT Liab | — | $0 | $1.1M |
| Total Liabilities | $2.4M | $2.0M | $2.7M |
| Shareholders' Equity | $-2.1M | $-1.7M | $-2.4M |
| Paid-In Capital | $71.8M | $74.7M | $76.0M |
| Retained Earnings | $-74.1M | $-76.7M | $-78.7M |
| Total L&E | $350.5K | $284.6K | $270.0K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $1.7M | $-2.6M | $-2.0M |
| Non-Cash Adjustments | $-3.3M | $278.0K | $653.9K |
| Working Capital Changes | $988.3K | $144.6K | $153.1K |
| Cash from Operations | $-619.7K | $-2.2M | $-1.2M |
| Cash from Investing | $-40.5K | $-2.9K | $0 |
| Debt Repayments | — | $10.0K | — |
| Share Buybacks | $50.0K | $0 | — |
| Cash from Financing | $651.8K | $2.3M | $1.3M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-8.4K | $82.0K | $73.5K |
| Beginning Cash | $21.8K | $13.4K | $95.4K |
| Ending Cash | $13.4K | $95.4K | $168.9K |
Frequently Asked Questions
How does United Health Products, Inc. make money?
The company currently operates without identifiable revenue-generating segments as cost of revenue and gross profit are listed at zero. All financial activity is characterized by non-cash adjustments rather than operational sales or service delivery. The balance sheet consists primarily of paid-in capital and lease-related assets with no active inventory or receivables.
What are the main risks for UEEC?
The primary risk is severe liquidity distress evidenced by negative operating cash flow of $1.2M against only $169k in ending cash. Investors face an extreme equity dilution risk due to the massive $78.7M retained earnings deficit relative to a negative shareholders' equity position. The company faces solvency risk with current liabilities of $1.6M exceeding total assets and zero operating revenue streams.
What is UEEC's competitive advantage?
The company possesses a structural advantage in reporting zero operating expenses, which artificially inflates gross margin metrics when revenue exists elsewhere or distorts loss calculations. There are no tangible product moats given the absence of cost of revenue and inventory data. The firm maintains a clean ledger with zero foreign exchange exposure and no income tax expense liability.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.